As one of the most important findings of this study, we have demonstrated by the serial transplantation assay that systemically-administered JNK inhibitor quite efficiently deprives CSCs/CSLCs of their capacity to sustain tumor growth in vivo. The gene discussed is MAPK8; the disease is neoplasm.